NCT02322229View on ClinicalTrials.gov

Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 26, 2015

Primary Completion Date

December 11, 2015

Study Completion Date

May 9, 2016

Conditions
Vitreomacular TractionVitreomacular Adhesion
Interventions
DRUG

Ocriplasmin 0.125 mg in a 0.1 mL volume

Trial Locations (1)

2113

Contact Alcon Laboratories (Australia) for Trial Locations, New South Wales

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY